StockData
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$14.10−2.02 (-12.53%)

Close on Nov 16, 2026Market cap $102.43MP/E –Yield –

Cue Biopharma total assets

Total assets on the balance sheet at the end of each period.

Cue Biopharma's total assets was $30.71M at Jun 30, 2026. For fiscal 2025 it was $42.21M, up 31.1% from the year before. The highest annual figure on record is $99.53M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$42.21M+31.1%
FY2024Dec 31, 2024$32.19M-47.7%
FY2023Dec 31, 2023$61.53M-32.6%
FY2022Dec 31, 2022$91.28M+9.5%
FY2021Dec 31, 2021$83.40M-16.2%
FY2020Dec 31, 2020$99.53M+39.0%
FY2019Dec 31, 2019$71.61M+57.8%
FY2018Dec 31, 2018$45.36M-32.2%
FY2017Dec 31, 2017$66.95M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$30.71M-24.6%
Q1 FY2026Mar 31, 2026$30.88M+38.7%
Q4 FY2025Dec 31, 2025$42.21M+31.1%
Q3 FY2025Sep 30, 2025$31.64M-29.4%
Q2 FY2025Jun 30, 2025$40.71M-3.8%
Q1 FY2025Mar 31, 2025$22.25M-58.8%
Q4 FY2024Dec 31, 2024$32.19M-47.7%
Q3 FY2024Sep 30, 2024$44.81M-35.0%
Q2 FY2024Jun 30, 2024$42.33M-42.1%
Q1 FY2024Mar 31, 2024$53.95M-33.9%
Q4 FY2023Dec 31, 2023$61.53M-32.6%
Q3 FY2023Sep 30, 2023$68.89M-9.7%
Q2 FY2023Jun 30, 2023$73.16M-13.7%
Q1 FY2023Mar 31, 2023$81.68M-9.9%
Q4 FY2022Dec 31, 2022$91.28M+9.5%
Q3 FY2022Sep 30, 2022$76.30M-3.3%
Q2 FY2022Jun 30, 2022$84.75M-5.5%
Q1 FY2022Mar 31, 2022$90.70M+2.2%
Q4 FY2021Dec 31, 2021$83.40M-16.2%
Q3 FY2021Sep 30, 2021$78.88M-26.0%
Q2 FY2021Jun 30, 2021$89.67M-11.5%
Q1 FY2021Mar 31, 2021$88.72M+46.3%
Q4 FY2020Dec 31, 2020$99.53M+39.0%
Q3 FY2020Sep 30, 2020$106.62M+135.8%
Q2 FY2020Jun 30, 2020$101.35M+142.7%
Q1 FY2020Mar 31, 2020$60.65M+34.2%
Q4 FY2019Dec 31, 2019$71.61M+57.8%
Q3 FY2019Sep 30, 2019$45.21M+1.4%
Q2 FY2019Jun 30, 2019$41.76M-21.4%
Q1 FY2019Mar 31, 2019$45.19M-23.8%
Q4 FY2018Dec 31, 2018$45.36M-32.2%
Q3 FY2018Sep 30, 2018$44.58M–
Q2 FY2018Jun 30, 2018$53.11M–
Q1 FY2018Mar 31, 2018$59.33M–
Q4 FY2017Dec 31, 2017$66.95M–

More Cue Biopharma figures

See a number that looks wrong?